DOCSLIB.ORG

Text Draft from 26.08.2015 <Invented Name> 1 Mg/G Cream Page 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Text Draft from 26.08.2015 <Invented Name> 1 Mg/G Cream Page 1 Text draft from 26.08.2015 <invented name> 1 mg/g cream Page 1 cream Dokument1 __________________________________________________________________________ SUMMARY OF PRODUCT CHARACTERISTICS / SmPC 1. NAME OF THE MEDICINAL PRODUCT <invented name> 1 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g cream contains 1 mg adapalene Excipients with known effect: 2 mg methylparahydroxybenzoate, 1 mg propylparahydroxybenzoate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Cream White cream 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Topical facial treatment of acne vulgaris where comedones predominate and papules and pustules are present. 4.2 Posology and method of administration <invented name> should be applied thinly once a day to the affected areas before retiring and after washing. Before application of <invented name>, the skin should be washed and thoroughly dried. The cream should be applied thinly with the fingertips to the affected areas. <invented name> is only for external use. Clinical improvement is seen within a time period of 4 to 8 weeks and continues during further treatment. Sufficient clinical experience is available for up to a 12 week treatment period. The duration of treatment is decided by the doctor depending on the clinical picture. With patients for whom it was necessary to temporarily discontinue treatment or reduce frequency of application, therapy may be resumed or the frequency of application may be restored when the reasons for previously mentioned measures no longer apply. Paediatric population The safety and efficacy of <invented name> in children below 12 years of age have not been established. No data are available. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Text draft from 26.08.2015 <invented name> 1 mg/g cream Page 2 cream Dokument1 __________________________________________________________________________ 4.4 Special warnings and precautions for use For external use only. If a reaction suggesting sensitivity or severe irritation occurs, use of the medication should be discontinued. If the degree of local irritation warrants, the patient should be directed to use the medication less frequently, to discontinue use temporarily until symptoms subside or to discontinue use altogether. Frequency of application may be restored or therapy resumed once it is judged that the patient can again tolerate the treatment. <invented name> should not come into contact with the eyes, mouth, angles of the nose, mucous membranes or open wounds. If product enters the eye, wash immediately with warm water. The product should not be applied to either broken (cuts and abrasions), sunburnt or eczematous skin, or in cases of dermatitis. <invented name> should not be used in patients with severe cases of acne vulgaris or secondary types of acne such as chloracne as the efficacy and tolerance have not been investigated. Patients should be informed that an increase in the frequency of use (more than twice daily) will not improve the therapeutic effect but will increase skin erythema and skin exfoliation. These symptoms are reversible. Exposure to sunlight and artificial UV irradiation, including sunlamps, should be minimized during use of adapalene. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. <invented name> may cause local irritation, therefore it is possible that concomitant use of peeling agents, abrasive cleansers, desiccating or irritant products may produce additive irritant effect (see section 4.5). Concomitant use of <invented name> and epilation (waxing) may in very rare cases lead to skin lesions. Epilation (waxing) should therefore be avoided on <invented name> treated areas of the skin. Paediatric population The safety and efficacy of <invented name> in children below 12 years of age has not been established. No data are available. Methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed). 4.5 Interaction with other medicinal products and other forms of interaction Absorption of adapalene through human skin is low, and therefore interaction with systemic medications is unlikely. Adapalene is essentially stable to oxygen and light and is chemically non-reactive. Cutaneous antiacne treatments such as erythromycin (up to 4%) or clindamycin phosphate (1% as the base) solutions or benzoyl peroxide water based gels (up to 10%) may be used in the morning when <invented name> is used at night as there is no mutual degradation or cumulative irritation. However, other retinoids or drugs with a similar mode of action should not be used concurrently with <invented name>. Text draft from 26.08.2015 <invented name> 1 mg/g cream Page 3 cream Dokument1 __________________________________________________________________________ <invented name>has a potential for mild local irritation, and therefore it is possible that concomitant use of peeling agents, abrasive cleansers, strong drying agents, astringents or irritant products (aromatic and alcoholic agents) may produce additive irritant effects (see section 4.4). 4.6 Fertility, pregnancy and lactation Pregnancy Animal studies by the oral route have shown reproductive toxicity at high systemic exposure (see section 5.3). Clinical experience with locally applied adapalene in pregnancy is limited but the few available data do not indicate harmful effects on early pregnancy or on the health of the foetus. Due to the limited available data and because a very weak cutaneous passage of adapalene is possible, adapalene should not be used during pregnancy. In case of unexpected pregnancy, treatment should be discontinued. Lactation No study on animal or human milk transfer was conducted after cutaneous application of adapalene. No effects on the suckling child are anticipated since the systemic exposure of the breast- feeding woman to adapalene is negligible. Adapalene can be used during breastfeeding. To avoid contact exposure of the infant, application of adapalene to the chest should be avoided when used during breast-feeding. 4.7 Effects on ability to drive and use machines Adapalene has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable effects System organ Frequency Adverse Drug Reaction class Skin and Common (≥1/100 Dry skin, skin irritation, skin burning sensation, subcutaneous to <1/10) erythema tissue disorders Uncommon Contact dermatitis, skin discomfort, sunburn, (≥1/1000 to pruritus, skin exfoliation, acne <1/100) Rare (≥1/10,000 to Pain of skin, skin swelling, <1/1000) Not known (cannot be estimated from Hypopigmentation, hyperpigmentation the available data)* Eye disorder Rare (≥1/10,000 to Eyelid irritation, eyelid erythema, eyelid <1/1000) pruritus, eyelid swelling Text draft from 26.08.2015 <invented name> 1 mg/g cream Page 4 cream Dokument1 __________________________________________________________________________ *Post marketing surveillance data In the case of moderate side effects, the frequency of use of <invented name> can be reduced to every second day for a two week period. If necessary, use of <invented name> can be temporarily discontinued until the symptoms have subsided. Methyl parahydroxybenzoate and Propyl parahydroxybenzoate may cause allergic reactions (possibly delayed). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 4.9 Overdose Adapalene products are not to be taken orally and are for cutaneous use only. If the medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling or discomfort may occur. Following accidental contact of <invented name> with the eyes, they should be washed with lukewarm water. The acute oral dose of <invented name> required to produce toxic effects in mice and rats is greater than 10 g/kg. Nevertheless, unless the amount accidentally ingested is small, an appropriate method of gastric emptying should be considered. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Anti-acne preparations for topical use, retinoids for topical use in acne ATC code: D10 AD03 Adapalene is an effective, chemically stable, retinoid-like compound with additional anti- inflammatory properties. Adapalene binds like tretinoin to specific nuclear receptors but, unlike tretinoin, not to cytosolic receptor binding proteins which are located outside of the nucleus. Adapalene applied cutaneously is comedolytic in an experimental acne-animal model (rhino-mouse). The rhino-mouse is characterized through occurrence of numerous comedoyltic-similar structures in the skin. Adapalene also has effects on the abnormal processes of epidermal keratinisation and differentiation, both of which play a fundamental role in the pathogenesis of acne vulgaris. The mode of action of adapalene is suggested to be a normalisation of differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Text draft from 26.08.2015 <invented name> 1 mg/g cream Page 5 cream Dokument1 __________________________________________________________________________ Adapalene is more anti-inflammatory than reference
Load more

Recommended publications
  • Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems
    pharmaceutics Review Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems Gemma Latter 1, Jeffrey E. Grice 2, Yousuf Mohammed 2 , Michael S. Roberts 2,3 and Heather A. E. Benson 1,* 1 School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth 6845, Australia; [email protected] 2 Therapeutics Research Group, The University of Queensland Diamantina Institute, School of Medicine, University of Queensland, Translational Research Institute, Brisbane 4109, Australia; jeff[email protected] (J.E.G.); [email protected] (Y.M.); [email protected] (M.S.R.) 3 School of Pharmacy and Medical Sciences, University of South Australia, Basil Hetzel Institute for Translational Health Research, Adelaide 5011, Australia * Correspondence: [email protected]; Tel.: +61-8-9266-2338 Received: 19 August 2019; Accepted: 17 September 2019; Published: 24 September 2019 Abstract: Acne vulgaris is a common inflammatory pilosebaceous condition that affects 80–90% of adolescents. Since the introduction of tretinoin over 40 years ago, topical retinoid products have been a mainstay of acne treatment. The retinoids are very effective in addressing multiple aspects of the acne pathology as they are comedolytic and anti-inflammatory, and do not contribute to antibiotic resistance or microbiome disturbance that can be associated with long-term antibiotic therapies that are a common alternative treatment. However, topical retinoids are associated with skin dryness, erythema and pain, and may exacerbate dermatitis or eczema. Thus, there is a clear need to target delivery of the retinoids to the pilosebaceous units to increase efficacy and minimise side effects in surrounding skin tissue.
    [Show full text]
  • Cumulative Irritation Comparison of Adapalene Gel and Solution with 2 Tazarotene Gels and 3 Tretinoin Formulations
    THERAPEUTICS FOR THE CLINICIAN Cumulative Irritation Comparison of Adapalene Gel and Solution With 2 Tazarotene Gels and 3 Tretinoin Formulations Alan Greenspan, MD; Christian Loesche, MD; Nancy Vendetti; Kathleen Georgeian; Richard Gilbert, PhD; Michel Poncet, PhD; Michael D. Baker, BS; Pascale Soto, RPh Forty-two subjects with normal skin were enrolled gel 0.025%, and 1 discontinued adapalene in a single-center study to assess the cumula- gel 0.1%. None of the subjects discontinued use tive irritancy potential of adapalene (Differin® of the white petrolatum or the adapalene solu- gel 0.1% and Differin solution 0.1%) compared tion 0.1%. Adapalene gel and solution 0.1% with tazarotene (Tazorac® gels 0.05% and 0.1%), were statistically (PϽ.01) less irritating than tretinoin (Retin-A Micro® gel 0.1%, Avita® cream both tazarotene gels 0.1% and 0.05%, tretinoin 0.025%, and Avita gel 0.025%), and white petro- microsphere gel 0.1%, and tretinoin gel 0.025%, latum (negative control). All test materials were and they were not statistically different from applied randomly, under occlusion, to sites tretinoin gel 0.025%. located on either side of the midline— the mid Cutis. 2003;72:76-81. thoracic area of the subjects’ backs. All patches were applied daily, Monday through Friday, to dapalene (Differin®) is a naphthoic-acid the same sites, unless the degree of reaction to derivative with retinoid activity that is a test product or adhesive necessitated removal A effective in the treatment of mild to moder- (grade 3). ate acne vulgaris.1-4 Adapalene, in both gel and Thirty-eight of the 42 subjects (90.5%) com- cream formulations, at the marketed and approved pleted the study.
    [Show full text]
  • Use of Undiluted Tea-Tree Oil As a Cosmetic
    Federal Institute for Risk Assessment (BfR) Use of undiluted tea-tree oil as a cosmetic Opinion of the Federal Insitute for Risk Assessment (BfR), 1th September 2003 Background Recently there has been an increasing amount of reports on contact-allergic eczema in con- junction with the use of tea-tree oil. Tea-tree oil is sold as a pure natural product, highly con- centrated and undiluted in cosmetics. Tea-tree oil is advertised as a universal remedy al- though there is no marketing authorisation as a pharmaceutical product. Concentrated tea-tree oil has been classified as harmful according to the self-classification of the International Fragrance Association (IFRA) and is labelled with R-phrases R 22 (harmful if swallowed) R 38 (irritating to skin) and R 65 (may cause lung damage if swallowed) as well as the symbol Xn (harmful) (IFRA Labelling Manual 1, 2001). These indications of health hazards are also part of the safety data sheets of raw material suppliers. At the 65th and 66th meetings of the Cosmetics Committee at the Federal Institute for Risk Assessment (BfR), health risks associated with the use of undiluted and highly concentrated tea-tree oil in cosmetic products were discussed extensively. Result Tea-tree oil is a mixture of various terpenes extracted from the Australian tea-tree. Undiluted tea-tree oil is a pure natural product. In the presence of atmospheric oxygen but also when exposed to light and higher temperatures, oxidation processes occur leading to the formation of peroxides, epoxides and endoperoxides which have a sensitising potency and may trigger allergic skin reactions.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Formulary Drug Removals
    July 2018 Formulary Drug Removals Below is a list of medicines by drug class that have been removed from your plan’s formulary. If you continue using one of the drugs listed below and identified as a Formulary Drug Removal, you may be required to pay the full cost. If you are currently using one of the formulary drug removals, ask your doctor to choose one of the generic or brand formulary options listed below. Category Formulary Drug Formulary Options Drug Class Removals Allergies BECONASE AQ flunisolide spray, fluticasone spray, mometasone spray, triamcinolone spray, Nasal Steroids / Combinations OMNARIS DYMISTA QNASL ZETONNA Anticonvulsants ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT Anti-infectives, Antibacterials E.E.S. GRANULES erythromycins Erythromycins / Macrolides ERYPED Anti-infectives, Antibacterials MINOCIN minocycline Tetracyclines DORYX doxycycline hyclate DORYX MPC MONODOX Anti-infectives, Antibacterials MACRODANTIN nitrofurantoin Miscellaneous Anti-infectives, Antivirals VALCYTE valganciclovir Cytomegalovirus * Anti-infectives, Antivirals MAVYRET EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6), VOSEVI 1 Hepatitis C * DAKLINZA EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6) OLYSIO TECHNIVIE
    [Show full text]
  • Mechanisms of Action of Azelaic Acid 15% Gel: Assessing Its Broad Antioxidant and Comedolytic Effects Zoe Diana Draelos, MD
    CCOSMETIOSMETICC CCONSULTATIONONSULTATION Mechanisms of Action of Azelaic Acid 15% Gel: Assessing Its Broad Antioxidant and Comedolytic Effects Zoe Diana Draelos, MD wo small studies were undertaken to investi- Dermatologic medications can have a similar versatility gate the ability of azelaic acid (AzA) 15% gel of action. For example, tetracyclines are used for their T to function as a comedolytic and as a topical antibacterial and anti-inflammatory qualities to treat antioxidant. The first study compared AzA 15% gel with acne. Sodium sulfacetamide and sulfur combinations are benzoyl peroxide (BPO) 5% gel as a comedolytic. Ten used for antibacterial, antifungal, and anti-inflammatory participants were randomized to apply AzA 15% gel on purposes for acne, seborrheic dermatitis, and rosacea. one shoulder and BPO 5% gel on the other shoulder One could argue that versatile ingredients can often be twice daily for 4 weeks, with a nontreated site on the more valuable than those that deliver a single, albeit central back serving as the control in all participants. powerful, effect. Comedone counts were obtainedCOS at baseline and week DERM4 An alternate dermatologic prescription that has mul- by examination of cyanoacrylate biopsies taken from tiple mechanisms of action is AzA 15% gel. Also known each site. The AzA 15% gel and BPO 5% gel produced as nonanedioic acid, AzA is a saturated dicarboxylic acid substantial decreases in mean comedones (12 to 0.9 and found naturally in wheat, rye, and barley. It is also pro- 14.9 to 1.6, respectively) from baseline to week 4 as duced by the yeast Pityrosporum ovale, a natural compo- compared with controlsDo (14.6 to 10.9).
    [Show full text]
  • Comparing 2.5%, 5%, and 10% Benzoyl Peroxide on Inflammatory
    Pharmacology and Therapeutics Comparing 2.5%, 5%, and 10% Benzoyi Peroxide on Inflammatory Acne Vulgaris OTTO H. MILLS, JR., PH.D., ALBERT M. KLICMAN, M.D., PH.D., PETER POCHI, M.D., AND HARRIET COMITE, M.D. From the Departments of Dermatology, University of Subjects, Materials, and Methods Pennsy/vania School of Medicine, Philadelphia, Pennsylvania, and Boston University School of Medicine, Clinical Studies Boston, Massachusetts The same methods were used to conduct three double- blind studies. After giving informed consent, subjects with mild to moderately severe inflammatory acne vulgaris of the face (minimum of 10 inflammatory lesions) were assigned to one of the three treatment groups. A total of 153 subjects, 74 men and 79 women (average age of 20 years), participated ABSTRACT: A 2.5% formulation of benzoyi peroxide was in the three studies. In the first, 25 subjects used 2.5% ben- compared with its vehicle, and with a 5% and a 10% proprietary zoyi peroxide gel and 25, the gel vehicle for this formulation. benzoyi peroxide gel preparation in three double-blind studies In the second, 26 used the 2.5 gel and 27, a 5% gel. The involving 153 patients with mild to moderately severe acne third study consisted of 25 subjects who used the 2.5% gel vulgaris. The 2.5% benzoyi peroxide formulation was more and 25, a 10% benzoyi peroxide gel. The subjects received effective than its vehicle and equivalent to the 5% and 10% no medications for any reasor\s during \he 4-week period concentrations in reducing the number of inflammatory lesions prior to the start of the study.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 04/01/11 This is not an all-inclusive list of available covered drugs and includes only Version 2011.9 managed categories. Refer to cover page for complete list of rules governing this PDL. • Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. • Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) • Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. • PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. • The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • 1 EMA Tender EMA/2017/09/PE, Lot 2 Impact of EU Label
    EMA tender EMA/2017/09/PE, Lot 2 Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: risk awareness and adherence Protocol • Prof. Anna Birna Almarsdóttir, Professor in Social and Clinical Pharmacy at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen • Prof. Marcel Bouvy, Professor of Pharmaceutical Care at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Rob Heerdink, Associate Professor at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Teresa Leonardo Alves, Researcher at the Centre for Health Protection, National Institute for Public Health and the Environment, The Netherlands. 1 Table of contents Background ...................................................................................................................... 3 Aims of the study ............................................................................................................. 4 Methods ........................................................................................................................... 4 Setting ........................................................................................... Error! Bookmark not defined. Study design ............................................................................................................................ 4 Population
    [Show full text]
  • Isotretinoin (Accutane) and Pregnancy
    Isotretinoin (Accutane®) This sheet talks about exposure to isotretinoin in a pregnancy or while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is isotretinoin? Isotretinoin is a prescription medication taken by mouth to treat severe cystic acne that has not responded to other treatments. Isotretinoin is a form of Vitamin A. It has been sold under brand names such as Accutane®, Absorica®, Amnesteem®, Claravis®, Epuris®, Clarus®, Myorisan®, Sotret®, and Zenatane®. How long after a woman stops taking isotretinoin should she wait to become pregnant? How long does isotretinoin stay in the body? It is recommended that a woman wait one month after stopping isotretinoin before trying to become pregnant. Usually, isotretinoin is no longer found in a woman’s blood 4-5 days after the last dose and most of its by-products should be gone within 10 days after the last dose. However, the time it takes isotretinoin to be cleared from the body can be longer in some people, which is why it is recommended to wait at least one month after stopping isotretinoin before trying to become pregnant. Can isotretinoin make it more difficult to get pregnant? Women who are trying to become pregnant should not be taking isotretinoin. There have been reports of irregular menstrual periods in some women taking isotretinoin. There are no reports of problems getting pregnant while taking isotretinoin. I just found out I am pregnant. Should I stop taking isotretinoin? Stop taking the medication right away. As soon as possible, call the healthcare provider who prescribed the isotretinoin and the healthcare provider who will be taking care of you during your pregnancy.
    [Show full text]
  • Isotretinoin for Neuroblastoma
    Isotretinoin for Neuroblastoma Isotretinoin (EYE so TRET in oin) is a form of vitamin A that is very concentrated. It can only be obtained by prescription. The oily liquid comes in a soft capsule. Brand names for this medicine are Amnesteem®, Absorica®, Claravis®, Myorisan® and Zenatane®. Isotretinoin is used to treat neuroblastoma, the most common type of cancer in children. This medicine is given along with other immunotherapy (cancer fighting) drugs during the active stage of illness. It may also be ordered to be taken during the maintenance phase of therapy. Usually isotretinoin is given after the child has received the medicine 131I- Metaiodobenzylguanidine (MIBG) and has had a Bone Marrow Transplant (BMT). Warnings If your child is allergic to retinoids, he should not take this medicine. When handling this drug, extreme care needs to be followed by women who are pregnant or breastfeeding. Isotretinoin can cause severe birth defects and can pass into breast milk. Someone else will need to give this medicine to your child. Because of the dangers of birth defects with isotretinoin, your child, your child’s doctor, and your pharmacy must register with the iPLEDGE™ program. To do this, go to www.ipledgeprogram.com. Failure to register means that your child will not get the medicine. When your child needs more medicine, the doctor will have to write a new prescription each time. How to give Isotretinoin can be given by mouth whole, buried in food whole, or dissolved and mixed with food. Always wear disposable gloves if there is a risk of touching the liquid inside the capsule.
    [Show full text]